Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease of unknown cause. It is the most common diagnosis among the interstitial lung diseases. As the population ages, respiratory therapist services provided to patients with IPF will increase. This educational activity for respiratory therapists will address the basics of diagnosis, new therapeutic advances, and disease-specific requirements for pulmonary rehabilitation, as well as provide information on how to best incorporate services to patients with IPF into their clinical practice.
The intended audience for this activity is respiratory therapists and other health care professionals involved in the treatment of patients with IPF.
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
This activity is supported by an educational grant from Genentech, Inc.
Education Provider: Vindico Medical Education.
Activity Chair
- Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC
Oklahoma Allergy and Asthma Clinic
Oklahoma City, OK- Disclosures
Speakers Bureau: Meda Pharmaceuticals, Monaghan Medical, Novartis
- Disclosures
Faculty
- Gregory P. Cosgrove, MD, FCCP
Chief Medical Officer, Pulmonary Fibrosis Foundation
Associate Professor, National Jewish Health and University of Colorado Denver
Denver, CO- Disclosures
Consulting Fee: Boehringer-Ingelheim, Genentech, Global Academy, Global Blood Therapeutics, Veracyte
Contracted Research: Boehringer-Ingelheim, Care Center Network and Patient Registry for the Pulmonary Fibrosis Foundation, Genentech
- Disclosures
- Amy L. Olson, MD, MSPH
Assistant Professor, Department of Medicine
Medical Director, Pulmonary Physiology Unit
National Jewish Health
Denver, CO- Disclosures
Speakers Bureau: Boehringer-Ingelheim
Non-CME Services Fees: Boehringer-Ingelheim, Genentech
Contracted Research: United Therapeutics
- Disclosures
Reviewer
- Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
- Disclosures
No relevant financial relationships to disclose.
- Disclosures
Vindico Medical Education staff have no relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
- Explain the criteria used in the differential diagnosis of IPF.
- Assess the evidence base on conventional management, as well as recently approved pharmacotherapies for the treatment of IPF.
- Determine which components should be included in a comprehensive pulmonary rehabilitation program for patients with IPF.